New drug tested for patients with severe autoimmune diseases who have run out of options
NCT ID NCT07193810
Summary
This is a very early study to check the safety and initial effects of an experimental drug called CC312. It is for adults with severe, relapsed forms of lupus, myositis, or scleroderma that have not improved with standard treatments. The main goal is to find a safe dose and see how the body handles the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Deyang People's Hospital
RECRUITINGDeyang, Sichuan, 618000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.